About 200 reports

Neurology Market: A BCC Research Overview Chapter ## Introduction Study Goals and Objectives Reasons for Doing this Study Scope of Report Information Sources Methodology Geographic Breakdown Analyst’s Credentials Chapter ## Summary and Highlights Chapter ## Market and Technology Background Neu

  • Neurology
  • Therapy
  • World
  • Market Shares
  • Market Size

Erenumab is the first and only human monoclonal antibody designed to block the calcitonin gene related peptide receptor.

  • Neurology
  • World
  • AstraZeneca PLC
  • Biogen Idec Inc.
  • Eli Lilly & Co.

Diseases and Disorders, ##(##). doi: ##. ##/ JDD. ## Miller, K. (2013).

  • Neurology
  • GW Pharmaceuticals plc
  • Insys Therapeutics, Inc.
  • Medical Marijuana, Inc.
  • Zynerba Pharmaceuticals, Inc.

Monoclonal antibodies such as mepolizumab and omalizumab are sometimes effective.

  • Cough And Cold
  • China
  • Demand
  • Market Size
  • Trade

Monoclonal antibodies such as mepolizumab and omalizumab are sometimes effective.

  • Cough And Cold
  • China
  • Demand
  • Market Size
  • GlaxoSmithKline plc

OTHER MONOCLONAL ANTIBODIES SUCH AS THOSE THAT RECOGNIZE CD## AND CD## ARE STILL UNDER INVESTIGATION.

  • Urology
  • Astellas Pharma Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • UROLOGIC ONCOLOGY, ASTRAZENECA PLC. ANNUAL REVENUE FORECAST ($BN), 2015-
  • UROLOGIC ONCOLOGY, BRISTOL-MYERS SQUIBB ANNUAL REVENUE FORECAST ($BN), 2015-

Antibody blockade of PD-## has showed promise in the treatment of several malignancies.

  • Neurology
  • Urology
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Pfizer Inc.

Anti-PD-## antibodies target the protein PD-##, which is expressed by immune cells.

  • Cough And Cold
  • Medical Biotechnology
  • Neurology
  • Urology
  • United States
  • Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Dormant Products
  • Familial Amyloid Neuropathies

The company develops monoclonal antibodies directed specifically at disease-causing proteins.

  • Cardiology
  • Endocrine Disease
  • Neurology
  • Therapy
  • Alnylam Pharmaceuticals, Inc.

Pasteur Institute NA NA MONOCLONAL ANTIBODY TO ANTAGONIZE FCGRIIA FOR AUTOIMMUNE ARTHRITIS, PULMONARY INFLAMMATION, SYSTEMIC ANAPHYLAXIS AND THROMBOCYTOPENIA - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description

  • Cough And Cold
  • Hormone
  • United States
  • Product Initiative
  • Insys Therapeutics, Inc.
  • HERPES ZOSTER (SHINGLES) - PIPELINE BY XBIOTECH INC, H2 2019

The company offers monoclonal antibodies treatment for various diseases.

  • Antifungal
  • Cough And Cold
  • Infectious Disease
  • Neurology
  • NanoViricides, Inc.
  • St George Street Capital Ltd
  • Products under Development by Companies, H2 2019

The molecules developed by Companies in Phase II, Preclinical, Discovery and Unknown stages are ##, ##, ## and ## respectively.

  • Neurology
  • Urology
  • World
  • Product Initiative
  • Cadila Healthcare Ltd
  • HERPES ZOSTER (SHINGLES) - PIPELINE BY XBIOTECH INC, H1 2018
  • HERPES ZOSTER (SHINGLES) - PIPELINE BY NANOVIRICIDES INC, H1 2018

VACCITECH LTD XBiotech Inc (XBiotech) is a bioscience company that discovers and develops True Human monoclonal antibodies the company provides monoclonal antibodies treatment for various diseases.

  • Infectious Disease
  • Neurology
  • United States
  • Product Initiative
  • GlaxoSmithKline plc
  • Familial Amyloid Neuropathies

The company develops monoclonal antibodies directed specifically at disease-causing proteins.

  • Chronic Disease
  • Neurology
  • Type 2 Diabetes
  • Urology
  • Alnylam Pharmaceuticals, Inc.

Avidity' s platform seeks to combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapeutics to potentially overcome barriers to the delivery of oligonucleotides and target genetic drivers of disease.

  • Dermatology
  • Neurology
  • World
  • Company
  • Deals & Alliance

Under the terms of consideration, AstraZeneca gains option rights to IPH##, an antibody targeting CD## monoclonal antibody, as well as four pre-clinical molecules from Innate.

  • Neurology
  • World
  • Company
  • Deals & Alliance
  • AstraZeneca PLC

The Center for Drug Evaluation and Research (CDER) oversees chemical-based drugs as well as monoclonal antibodies and cytokines.

  • Biopharmaceutical
  • Neurology
  • Therapy
  • United States
  • Product Initiative

Anti-neutrophil cytoplasmic auto-antibody (ANCA) -associated vasculitis (AAV).

  • Autoimmune Disease
  • Neurology
  • Urology
  • United States
  • ChemoCentryx, Inc.

IPH-## is an anti-C##aR-## monoclonal antibody.

  • Neurology
  • Urology
  • United States
  • Product Initiative
  • ChemoCentryx, Inc.
  • 4.1.2 ONCOLOGY - DEALS OF THE YEAR

Under the terms of consideration, AstraZeneca gains option rights to IPH##, an antibody targeting CD## monoclonal antibody, as well as four pre-clinical molecules from Innate.

  • Endocrine Disease
  • Neurology
  • World
  • Company
  • Deals & Alliance

Aimovig is the first and only fully human monoclonal antibody designed to specifically block the calcitonin gene-related peptide (CGRP) receptor; CGRP plays a critical role in migraine activation.

  • Neurology
  • Therapy
  • Urology
  • United States
  • Product Initiative

Most recently she served as the Worldwide Brand Director at Novartis Pharmaceuticals Corporation, where she was the global launch lead for Aimovig®, the first monoclonal antibody approved by the U. S.

  • Cough And Cold
  • Neurology
  • Urology
  • United States
  • AcelRx Pharmaceuticals, Inc.
  • with no significant toxicities and 50 percent overall response rate.

The drug candidate is a human monoclonal antibody.

  • Healthcare
  • Neurology
  • Urology
  • United States
  • Product Initiative

Syndax also develops SNDX-##, a monoclonal antibody that targets the CSF-## receptor.

  • Cough And Cold
  • Neurology
  • Oncology
  • Pharmaceutical
  • Genentech, Inc.

The drug candidate is a monoclonal antibody that inhibits binding of IL-## to the ST## receptor.

  • Cough And Cold
  • Neurology
  • Urology
  • United States
  • Product Initiative

Our VB-## platform comprises classical anti-MOSPD## monoclonal antibodies for inflammatory indications, as well as bi-specific antibody candidates for oncology.

  • Cough And Cold
  • Drug Development
  • Neurology
  • World
  • Product Initiative

Syndax also develops SNDX-##, a monoclonal antibody that targets the CSF-## receptor.

  • Cough And Cold
  • Neurological Disorder
  • Neurology
  • Urology
  • UCB S.A.

Trials conducted by companies in Phase II and Phase ## stand at ## and ## respectively.

  • Neurological Disorder
  • Neurology
  • Therapy
  • World
  • Product Initiative

University reported that when anti sema##A antibody is injected to vitreous body of the axotomized eye of animals it did not cause any signs of inflammation, irritation or any other changeswhich may indicate that this treatment is toxic.

  • Neurology
  • Therapy
  • Urology
  • United States
  • Regeneron Pharmaceuticals, Inc.
  • CLINICAL TRIAL PROFILE SNAPSHOTS

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Neurology
  • Pharmaceutical
  • World
  • Product Initiative
  • CSL Limited